Phaseline

Companies › ACADIA Pharmaceuticals

ACADIA Pharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 7 registered trials: 3 Phase 2, 2 Phase 3, 2 Phase 4; Neurology, Psychiatry, Metabolic and endocrine, Other; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ACP-204
5-HT2A receptor antagonist/inverse agonist
HTR2APhase 3Lewy Body Dementia Psychosis; Alzheimer's Disease PsychosisJan 2028
Carbetocin (ACP-101)
Oxytocin receptor agonist
OXTRPhase 3Hyperphagia in Prader-Willi Syndrome; Postpartum Hemorrhage–
ACP-211
Muscarinic M1 receptor positive allosteric modulator
CHRM1Phase 2Major Depressive Disorder (MDD)Aug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06173531Carbetocin (ACP-101)Phase 3Hyperphagia in Prader-Willi SyndromeMetabolic and endocrineAug 2025
NCT07284667ACP-211Phase 2Major Depressive Disorder (MDD)PsychiatryAug 2027
NCT06159673ACP-204Phase 2Alzheimer's Disease PsychosisNeurologyJan 2028
NCT07029581ACP-204Phase 2Lewy Body Dementia PsychosisNeurologyFeb 2028
NCT07401524Carbetocin (ACP-101)Phase 4Postpartum HemorrhageOtherMar 2028
NCT07636421Carbetocin (ACP-101)Phase 4Postpartum HemorrhageOtherApr 2028
NCT07095465ACP-204Phase 3Lewy Body Dementia PsychosisNeurologyFeb 2029

From the company's SEC filings

Cash and short-term investments of $976m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

HTR2A (1) CHRM1 (1) OXTR (1)

Companies with the same targets

Bristol-Myers Squibb Cybin IRL COMPASS Pathways Vanda Pharmaceuticals Intra-Cellular Therapies Definium Therapeutics US Sichuan Kelun Pharmaceutical Boryung Pharmaceutical Otsuka NeuroRx

Companies built like this

Alkermes PTC Therapeutics Neurocrine Biosciences Idorsia Pharmaceuticals Supernus Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.